Results 261 to 270 of about 114,065 (338)

V-H gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia [PDF]

, 2003
Amlot, P, Duke, VM, Foroni, L, Gandini, D, Heelan, B, Hoffbrand, AV, Lin, K, Mehta, AB, Sherrington, PD   +8 more
core  

Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape

The FEBS Journal, EarlyView.
The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto, Naike Casagrande, Emanuele Di Siena, Greta Carobolante, Lucrezia Camicia, Giorgia Schinello, Samanta Muzzin, Enrica Timis, Paola Spessotto, Maurizio Mongiat   +9 more
wiley   +1 more source

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

Influence of polyfunctional Tbet⁺ T cells on specific clinical events in chronic lymphocytic leukaemia. [PDF]

Front Immunol
Lim YJ, Duckworth AD, Clarke K, Kennedy P, Karpha I, Oates M, Gornall M, Kalakonda N, Slupsky JR, Pettitt AR.   +9 more
europepmc   +1 more source

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China. [PDF]

EClinicalMedicine
Wang T, Yan Y, Wang H, Sun Y, Liu X, Lyu R, Xiong W, An G, Liu W, Xu Y, Deng S, Wang Q, Du C, Huang L, Zou D, Zhao Y, Qiu L, Li Z, Yi S.   +18 more
europepmc   +1 more source

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group. [PDF]

EClinicalMedicine
Quinquenel A, Letestu R, Le Garff-Tavernier M, Morisset S, Subtil F, Aurran T, Laribi K, Cymbalista F, Lévy V, Simon L, Roos-Weil D, Leblond V, Dilhuydy MS, Tomowiak C, Dartigeas C, Guièze R, Tournilhac O, Ferrant E, de Guibert S, Feugier P, Merabet F, Leprêtre S, Carassou P, Gay J, Hivert B, Fornecker LM, Dupuis J, Molina L, Villemagne B, Cartron G, Drenou B, Mahé B, Benbrahim O, Cahu X, Portois C, Ysebaert L, Nguyen-Khac F, Dahmani A, Quiney C, Rouillé V, Delmer A, Michallet AS.   +41 more
europepmc   +1 more source

Amyotrophic lateral sclerosis in a patient with chronic lymphocytic leukaemia and drug related sarcoid-like reaction. [PDF]

BMC Neurol
Freiha J, Grand E, Marshall B, Arunchalam R, Pinto A, Osman C.   +5 more
europepmc   +1 more source

Spontaneous tumour lysis syndrome in chronic lymphocytic leukaemia: an unanticipated complication of an undiagnosed disease. [PDF]

BMJ Case Rep
Verma Saluja K, Arya Y, Sukheeja D, Suman CP.   +3 more
europepmc   +1 more source

9. Chronic Lymphocytic Leukaemia

Annals of Oncology, 2005
openaire   +1 more source

Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience. [PDF]

Hematol Oncol
Innocenti I, Tomasso A, Giannarelli D, Scarfò L, Murru R, Visentin A, Frustaci AM, Morelli F, Vitale C, Mosca A, Sanna A, Farina G, Laureana R, Gentile M, Galitzia A, Pasquale R, Autore F, Olivieri J, Romeo A, Deodato M, Stirparo L, Corbingi A, Innao V, Perutelli F, Martini F, Sportoletti P, Fresa A, Del Principe MI, Tedeschi A, Coscia M, Ghia P, Laurenti L.   +31 more
europepmc   +1 more source